Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BBT-877 in Healthy Adults
NCT03830125Phase 1Completed
- Sponsor
- Bridge Biotherapeutics
- Start
- Feb 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LCB17-0877 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Bridge Biotherapeutics. Primary endpoint: Treatment Emergent Adverse Events. Started Feb 2019; status: completed.
02
Drugs
LCB17-0877
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03830125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830125.